These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1552422)

  • 1. Management of the febrile patient with cancer and neutropenia.
    Buchanan GR
    J Pediatr; 1992 Apr; 120(4 Pt 1):669-70. PubMed ID: 1552422
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever.
    Jun HX; Zhixiang S; Chun W; Reksodiputro AH; Ranuhardy D; Tamura K; Matsumoto T; Lee DG; Purushotaman SV; Lim V; Ahmed A; Hussain Y; Chua M; Ong A; Liu CY; Hsueh PR; Lin SF; Liu YC; Suwangool P; Jootar S; Picazo JJ
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S128-32; discussion S133-40. PubMed ID: 16253480
    [No Abstract]   [Full Text] [Related]  

  • 3. Outpatient antibiotic therapy in febrile neutropenic patients undergoing high-dose chemotherapy and autologous bone marrow support.
    Rubenstein EB; Rolston K; Elting L
    J Clin Oncol; 1994 Nov; 12(11):2516-7. PubMed ID: 7964970
    [No Abstract]   [Full Text] [Related]  

  • 4. Fosfomycin in paediatric cancer patients: a feasible alternative to glycopeptides?
    Hepping N; Simon A
    Int J Antimicrob Agents; 2009 Apr; 33(4):389. PubMed ID: 19097756
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutropenic fever of undetermined origin (N-FUO): why not use the naproxen test?
    Chang JC; Hawley HB
    Cancer Invest; 1995; 13(4):448-50. PubMed ID: 7627730
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antibiotics in patients with fever and neutropenia].
    Kern WV
    Dtsch Med Wochenschr; 2013 Jun; 138(23):1217-20. PubMed ID: 23720174
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
    Paganini H; Rodriguez-Brieshcke T; Zubizarreta P; Latella A; Firpo V; Casimir L; Armada A; Fernández C; Cáceres E; Debbag R
    Cancer; 2001 Apr; 91(8):1563-7. PubMed ID: 11301406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient treatment of febrile neutropenic patients with cancer.
    Rubenstein EB; Rolston KV
    Eur J Cancer; 1995; 31A(1):2-4. PubMed ID: 7695973
    [No Abstract]   [Full Text] [Related]  

  • 10. Cefepime and mortality.
    Mebis J; Goossens H; Berneman ZN
    Lancet Infect Dis; 2009 Oct; 9(10):585-6. PubMed ID: 19778758
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antimicrobial therapy of febrile neutropenia--current developments].
    Karthaus M; Cornely OA; Südhoff T; Meran J
    Wien Med Wochenschr; 2001; 151(3-4):66-72. PubMed ID: 11789421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition.
    Jones GR; Konsler GK; Dunaway RP; Gold SH; Cooper HA; Wells RJ
    J Pediatr; 1994 May; 124(5 Pt 1):703-8. PubMed ID: 8176555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Summary and comments.
    Sinkó J; Kullberg BJ; Edwards JE; Anaissie E
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i41-3. PubMed ID: 19372182
    [No Abstract]   [Full Text] [Related]  

  • 14. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
    N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possibilities and limits of ambulatory supportive measures in oncology exemplified by antibiotic therapy of febrile neutropenia].
    Karthaus M; Meran JG; Geissler RG; Böhme A; Jürgens H; Ganser A
    Wien Med Wochenschr; 1998; 148(18):427-32. PubMed ID: 9888179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of antibiotics in febrile neutropenic patients with cancer].
    Villegas JB; Gavilán MG
    Rev Esp Quimioter; 1999 Jun; 12(2):104-6. PubMed ID: 10562669
    [No Abstract]   [Full Text] [Related]  

  • 18. Infectious complications in the child with cancer. I. Pathophysiology of the compromised host and the initial evaluation and management of the febrile cancer patient.
    Pizzo PA
    J Pediatr; 1981 Mar; 98(3):341-54. PubMed ID: 7009815
    [No Abstract]   [Full Text] [Related]  

  • 19. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here?
    Pizzo PA
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i16-7. PubMed ID: 19372174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia.
    Simon A; Gröger N; Wilkesmann A; Hasan C; Wiszniewsky G; Engelhart S; Kramer MH; Bode U; Ammann RA; Fleischhack G
    Int J Antimicrob Agents; 2006 Nov; 28(5):417-22. PubMed ID: 17046210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.